MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Net Debt 2011-2026 | NEOG
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 751 M | 723 M | 725 M | -41.2 M | -73.1 M | - | -41.7 M | -83.1 M | -77.6 M | -55.3 M | -66.1 M | -40.7 M | -50 M | -49 M | -35.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 751 M | -83.1 M | 113 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
231 M | $ 8.99 | 1.35 % | $ 599 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-6.88 M | $ 13.73 | 0.59 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
-108 M | $ 25.9 | 0.27 % | $ 719 M | USA |
 |
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
-842 M | $ 67.32 | 1.48 % | $ 26.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
1.15 B | $ 88.75 | 1.8 % | $ 11.1 B | USA |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 153.71 | 1.14 % | $ 7.62 B | USA |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 17.6 | 1.62 % | $ 938 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-916 M | $ 103.94 | 0.09 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 15.43 | 3.21 % | $ 467 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
14.5 M | $ 16.59 | -4.05 % | $ 2.15 B | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 100.49 | 2.95 % | $ 8.29 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
-1.04 M | $ 2.89 | 1.76 % | $ 93.8 K | USA |
 |
IQVIA Holdings
IQV
|
12 B | $ 168.43 | 2.15 % | $ 29 B | USA |
 |
Danaher Corporation
DHR
|
14 B | $ 195.21 | 2.0 % | $ 139 B | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.38 | 1.47 % | $ 414 M | USA |
 |
Illumina
ILMN
|
-494 M | $ 120.84 | 1.31 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 198.61 | -0.17 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.24 B | $ 112.75 | 0.82 % | $ 34.3 B | USA |
 |
BioNano Genomics
BNGO
|
-2.64 M | $ 1.13 | 1.8 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
-12.1 M | $ 8.75 | 3.92 % | $ 248 M | Israel |
 |
NeoGenomics
NEO
|
187 M | $ 8.27 | 0.36 % | $ 1.06 B | USA |
 |
Lantheus Holdings
LNTH
|
213 M | $ 80.45 | 2.48 % | $ 5.43 B | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-11.9 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
-360 M | $ 455.15 | 0.33 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
2.06 B | $ 1 206.72 | 0.63 % | $ 24.9 B |  Schweiz |
 |
Celcuity
CELC
|
82.8 M | $ 114.11 | -0.69 % | $ 4.5 B | USA |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
71.3 M | $ 17.73 | 1.9 % | $ 397 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-107 M | $ 47.28 | 5.04 % | $ 2.83 B | USA |
 |
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
-177 M | $ 198.38 | 0.35 % | $ 19.5 B | USA |